Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OK's Vanda’s Hetlioz for sleep disorder in blind

This article was originally published in Scrip

Executive Summary

Shares of Vanda Pharmaceuticals gained $2.53, or about 20%, on 31 January after the FDA approved the company’s drug Hetlioz (tasimelteon) as circadian regulator to treat non-24-Hour (non-24), a rare sleep-wake disorder, in patients with total blindness.

You may also be interested in...



Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

The latest drug development news and highlights from our US FDA Performance Tracker.

Vanda Not Ready To Give Up On Jet Lag Indication For Hetlioz Despite CRL

Complete response letter follows July deficiencies letter that made approval seem highly unlikely. Vanda called the setback perplexing and said it plans to continue working to get jet lag disorder added to the Hetlioz label.

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

Related Companies

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel